This is a Vertex news story, published by Recursive Adaptation | Nicholas Reville, that relates primarily to HHS news.
For more Vertex news, you can click here:
more Vertex newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Recursive Adaptation | Nicholas Reville, you can click here:
more news from Recursive Adaptation | Nicholas RevilleOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
avoidable new opioid addictions. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest many opioid addictions news, Opioid Prescriptions news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
opioid painkillersRecursive Adaptation | Nicholas Reville
•72% Informative
There’s a strong non-addictive, opioid-replacing painkiller coming soon, but most patients won't be able to get it.
Suzetrigine is a novel non-opioid, sodium channel painkiller with no addictive potential, from mid-size pharma company Vertex .
Insurance providers will not pay for suzetrigin unless a doctor can show that a patient has tried a cheaper generic drug first and it was ineffective.
Federal government could offer Vertex $120 million in exchange for making suzetrigine available at generic prices.
The result is that patients are safer, addictions are avoided, and huge downstream costs from addiction are saved.
HHS could negotiate an arrangement with Vertex to sell the drug at cost, regardless of the payer.
HHS policy and supporting legislation could create an ongoing mechanism for arrangements with drug makers for any new opioid-replacing painkiller as it enters the market.
This could involve creating a default negotiation structure, similar to the Medicaid Drug Rebate Program (MDRP) that drug makers can opt for, designed to increase their projected revenues modestly.
VR Score
67
Informative language
62
Neutral language
19
Article tone
informal
Language
English
Language complexity
60
Offensive language
possibly offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
11
Source diversity
8
Affiliate links
no affiliate links